MRNA Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of -117.16% compared to Moderna's net margin of 23.56%. Moderna's return on equity of -29.09% beat Gilead Sciences's return on equity of 2.5%.

Moderna has a consensus price target of $53.44, signalling upside risk potential of 74.24%. On the other hand Gilead Sciences has an analysts' consensus of $111.71 which suggests that it could fall by -0.07%. Given that Moderna has higher upside potential than Gilead Sciences, analysts believe Moderna is more attractive than Gilead Sciences.

Moderna has a beta of 1.863, which suggesting that the stock is 86.269% more volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.213, suggesting its less volatile than the S&P 500 by 78.702%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.77% to investors and pays a quarterly dividend of $0.79 per share. Moderna pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Moderna quarterly revenues are $956M, which are smaller than Gilead Sciences quarterly revenues of $7.6B. Moderna's net income of -$1.1B is lower than Gilead Sciences's net income of $1.8B. Notably, Moderna's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 302.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.77x versus 4.89x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -117.16% compared to Moderna's net margin of 15.24%. Moderna's return on equity of -29.09% beat Johnson & Johnson's return on equity of 19.98%.

Moderna has a consensus price target of $53.44, signalling upside risk potential of 74.24%. On the other hand Johnson & Johnson has an analysts' consensus of $169.07 which suggests that it could grow by 3.27%. Given that Moderna has higher upside potential than Johnson & Johnson, analysts believe Moderna is more attractive than Johnson & Johnson.

Moderna has a beta of 1.863, which suggesting that the stock is 86.269% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.473, suggesting its less volatile than the S&P 500 by 52.686%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.03% to investors and pays a quarterly dividend of $1.24 per share. Moderna pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna quarterly revenues are $956M, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Moderna's net income of -$1.1B is lower than Johnson & Johnson's net income of $3.4B. Notably, Moderna's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 28.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.77x versus 4.47x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -117.16% compared to Moderna's net margin of 32.59%. Moderna's return on equity of -29.09% beat Eli Lilly and's return on equity of 80.24%.

Moderna has a consensus price target of $53.44, signalling upside risk potential of 74.24%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 22.85%. Given that Moderna has higher upside potential than Eli Lilly and, analysts believe Moderna is more attractive than Eli Lilly and.

Moderna has a beta of 1.863, which suggesting that the stock is 86.269% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Moderna pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna quarterly revenues are $956M, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Moderna's net income of -$1.1B is lower than Eli Lilly and's net income of $4.4B. Notably, Moderna's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 70.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.77x versus 16.51x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -117.16% compared to Moderna's net margin of 31.35%. Moderna's return on equity of -29.09% beat Vertex Pharmaceuticals's return on equity of -3.23%.

Moderna has a consensus price target of $53.44, signalling upside risk potential of 74.24%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $497.01 which suggests that it could grow by 0.91%. Given that Moderna has higher upside potential than Vertex Pharmaceuticals, analysts believe Moderna is more attractive than Vertex Pharmaceuticals.

Moderna has a beta of 1.863, which suggesting that the stock is 86.269% more volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.629%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moderna pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Moderna quarterly revenues are $956M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Moderna's net income of -$1.1B is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Moderna's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.77x versus 11.60x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.